Preclinical

The Cell Therapy Analytical Development Summit Europe is the leading industry-defining forum in Europe made exclusively for analytical, CMC, QC, process development and regulatory experts. Next generation cell therapies are emerging as game changing treatments for cancer and beyond, but given their increasing complexities, developing robust, reliable, and in-depth analytical assays is critical to prove their safety and quality to the regulatory authorities.

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

New for 2022, take advantage of two tracks of content showcasing; Pre-IND & Early Clinical Development Exploring Assay Development for Best-in-Class Early-Stage Characterization; Establishing the Safety of Cell Therapy Products with Comprehensive Analytics Starting with the End-in-Mind: Considerations for Raw & Starting Material Analysis Optimizing Early-Stage Analytics to Bolster Speed to IND Submission & Phase 1 Launch Clinical Development & Commercialization; Improving Method Validation to Prepare for Successful Clinical Production; Approaching Later-Stage Analytical & Process Technology Transfers; Scaling Up from Clinical Development to Commercialization & Preparing for Release Optimizing Analytics During Manufacturing, Dealing with Process Changes

Join the CAR-TCR Summit Europe to connect with those trailblazing the next wave of CAR and TCR based approaches from preclinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster. Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumor indications, and leave understanding the technical strategies to build automated, closed-system manufacturing processes to ensure vein to vein time is less than a week. Promising data-driven case studies outlining next generation product design, clinical trial set-up and manufacturing processes, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies across all emerging cell types including T, NK, macrophage, gamma delta T and iPSC.

After the explosive news that CAR-T therapies can now be considered curative, now is the time to unite with your industry, from the long-standing commercial giants to the trailblazing pioneers, and discover new strategies for everything from discovery to early phase development to commercialization. Gain end-to-end insights from both established thought leaders and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. Across 3 conference days with 8 tracks, 13 Workshops, 1 Bootcamp and 1 Focus Day, 200+ CAR and TCR experts will lead you and 1,000 of your peers in discussions that will accelerate your pipeline and bring much-needed treatments to patients faster.

Allogeneic therapies are game-changing in the field of cell therapy, overcoming current critical barriers around cost, production, and accessibility currently faced with autologous, personalized treatments. With billions of pounds worth of investment seen in collaborations to advance the development of allogeneic CAR-T, NK, macrophage and iPSC-based therapies, the excitement in this space is explosive! Capitalizing on this “holy grail” approach at the 4th Allogeneic Cell Therapies Summit, the leading industry-focused meeting captured cutting-edge advances across pre-clinical development, translation, manufacturing, supply and storage, to accelerate the successful clinical translation of your allogeneic pipeline. This fast-evolving community compared and contrasted platform technology to improve durability and persistence, review the strategies for selecting gold-standard donor starting material, and learn about the latest developments in gene engineering and serve as the “off-the-shelf” ready-to-use therapeutic agents for large-scale clinical applications. Over 300 experts from pharma, biotech and leading academia united in Boston to collaborate and share lessons learned to streamline scalable manufacturing processes, define optimal cryopreservation conditions and define regulatory expectations to achieve the huge demand for these treatments.2022 showcased the work of Allogene, Atara Biotherapeutics, Cellectis, Celularity, ImmunityBio, and more, don’t miss out on the most important meeting of the cell therapy calendar in 2023.

Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest developments in immuno-oncology, while providing access to a comprehensive 3-day program and extensive networking opportunities that CHI’s IO Summit provides.

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

Advance your innovative biologics pipeline and elevate your engineering, targets and machine learning strategies – accelerating your path to the clinic and beyond.

Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligonucleotides, peptides, mRNA, drug delivery and partnering strategies — from discovery to market, with an emphasis on the European region. Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development. Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.